FDA Approves Adjuvant Atezolizumab for ctDNA MRD–Positive MIBC

The FDA approved atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for the adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.¹

The approval marks the first time a biomarker-guided, ctDNA-directed treatment strategy has received regulatory authorization in the adjuvant bladder cancer setting, establishing a new treatment paradigm built on molecular rather than radiographic evidence of residual disease.

Concurrent with the approvals, the FDA also authorized Signatera CDx as a companion diagnostic device to identify patients with MIBC following cystectomy who have ctDNA-detectable molecular residual disease and are therefore eligible for adjuvant treatment with either Tecentriq or Tecentriq Hybreza.

The approval was based on findings from the IMvigor011 trial in which, at a median follow-up of 16.1 months, atezolizumab produced a statistically significant reduction in the risk of disease recurrence or death in ctDNA-positive patients. The median disease-free survival (DFS) was 9.9 months (95% CI, 7.2-12.7) in the atezolizumab arm compared with 4.8 months (95% CI, 4.1-8.3) in the placebo arm, translating to a 36% reduction in the risk of recurrence or death (HR, 0.64; 95% CI, 0.47-0.87; P =.0047).¹

The DFS benefit was generally consistent across key clinical subgroups, including patients who would traditionally have been excluded from prior adjuvant trials, such as those with pT2N0 disease, suggesting that ctDNA positivity provides prognostic and predictive value beyond conventional pathologic staging.

Overall survival data also crossed the threshold for statistical significance. Patients in the atezolizumab arm had a median OS of 32.8 months (95% CI, 27.7 months-not estimable) compared with 21.1 months (95% CI, 14.7 months-not estimable) for those receiving placebo, representing a 41% reduction in the risk of death (HR, 0.59; 95% CI, 0.39-0.90; P =.0131).

"For the patients and families, the 'watch and wait' period after a cystectomy is often defined by uncertainty. This ctDNA-guided approach can enable doctors to use serial ctDNA MRD testing to identify who is at a higher risk of recurrence and move quickly toward immunotherapy for those who may benefit from it, while allowing others to safely avoid additional treatment and its associated side effects," Meri-Margaret Deoudes, CEO of the Bladder Cancer Advocacy Network, stated in a news release.³

IMvigor011 Study Design

IMvigor011 (NCT04660344) was a global, multicenter, randomized, double-blind, placebo-controlled phase 3 trial that enrolled 761 patients with MIBC and no radiographic evidence of disease into a surveillance phase beginning six to 24 weeks after radical cystectomy with lymph node dissection. Enrolled patients underwent serial ctDNA testing using the Signatera assay for up to one year following surgery.²

Of the 761 patients monitored, 250 tested ctDNA-positive and were eligible for randomization. These patients were assigned in a 2:1 ratio to receive either atezolizumab 1,680 mg intravenously every four weeks (n = 167) or placebo (n = 83) for up to 12 cycles or one year, whichever occurred first, unless disease recurrence or unacceptable toxicity intervened. The primary end point was investigator-assessed disease-free survival, with overall survival as a key secondary endpoint.

Safety

The tolerability profile of atezolizumab in IMvigor011 was consistent with the established safety profile of the agent across its prior approved indications, with no new safety signals identified. Grade 3 or 4 adverse events occurred in 28% of patients in the atezolizumab arm and 22% in the placebo arm. Immune-mediated adverse events of any grade were reported in 38.8% of atezolizumab-treated patients versus 12.0% of those receiving placebo, with grade 3/4 immune-mediated events occurring in 4.8% and 1.2% of patients, respectively. The prescribing information for both formulations includes warnings and precautions for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicity.²

“Combining our cancer immunotherapy Tecentriq with state-of-the-art MRD testing allows more precise identification of patients who are candidates for intervention and those who might safely avoid unnecessary treatment,” Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development, stated in the news release.³ “We look forward to delivering this first of its kind ctDNA-guided regulatory approval to bladder cancer physicians and patients in the US.”

REFERENCES

1. U.S. Food and Drug Administration. FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease. FDA. May 15, 2026. Accessed May 15, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular

2. Powles T, Kann AG, Castellano D, et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl J Med. 2025;393:1632-1644. doi:10.1056/NEJMoa2511885

3. Genentech. FDA approves Genentech's Tecentriq for adjuvant muscle-invasive bladder cancer with ctDNA-guided treatment. News release. Genentech; May 15, 2026. Accessed May 15, 2026. https://www.gene.com/media/press-releases/15112/2026-05-15/fda-approves-genentechs-tecentriq-for-ad